Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice

甲基转移酶抑制剂可恢复小鼠皮肤T细胞淋巴瘤中SATB1的保护活性。

阅读:4
作者:Carly M Harro ,Jairo Perez-Sanz ,Tara Lee Costich ,Kyle K Payne ,Carmen M Anadon ,Ricardo A Chaurio ,Subir Biswas ,Gunjan Mandal ,Kristen E Rigolizzo ,Kimberly B Sprenger ,Jessica A Mine ,Louise C Showe ,Xiaoqing Yu ,Kebin Liu ,Paulo C Rodriguez ,Javier Pinilla-Ibarz ,Lubomir Sokol ,Jose R Conejo-Garcia

Abstract

Cutaneous T cell lymphoma (CTCL) has a poorly understood etiology and no known cure. Using conditional knockout mice, we found that ablation of the genomic organizer special AT-rich sequence-binding protein 1 (Satb1) caused malignant transformation of mature, skin-homing, Notch-activated CD4+ and CD8+ T cells into progressively fatal lymphoma. Mechanistically, Satb1 restrained Stat5 phosphorylation and the expression of skin-homing chemokine receptors in mature T cells. Notably, methyltransferase-dependent epigenetic repression of SATB1 was universally found in human Sézary syndrome, but not in other peripheral T cell malignancies. H3K27 and H3K9 trimethylation occluded the SATB1 promoter in Sézary cells, while inhibition of SUV39H1/2 methyltransferases (unlike EZH2 inhibition) restored protective SATB1 expression and selectively abrogated the growth of primary Sézary cells more effectively than romidepsin. Therefore, inhibition of methyltransferases that silence SATB1 could address an unmet need for patients with mycosis fungoides/Sézary syndrome, a set of incurable diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。